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Abstract: The pharmacokinetics of 16-dehydropregnenolone (16- DHP), a sterols compound isolated from Solanum
lyratum Thunb., was investigated in rats following a single intramuscular administration (40 mglkg). The concentration
of 16-DHP in rat plasma was determined by a high performance liquid chromatography (HPLC) method with UV
detection. Levonorgestrel was used as the internal standard (IS). The pharmacokinetic parameters of 16-DHP were
derived by non-compartmental method. After a single intramuscular administration, the maximum plasma concentration
(CmaJ was (289 ± 25)nglmL, time to reach Cmax(t max ) was (0.38±0.14) h, the elimination half-life (11/2) was (2.5±
1.1) h, the area under the plasma concentration-time curve from time zero to the time of the last measurable
concentration (AUC<o.l» was (544 ± 73)ng' h/mL. The results indicated that 16-DHP was absorbed quickly and eliminated
rapidly in rats after the intramuscular injection.
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1 Introduction
Solanum lyratum Thunb. is a popular medicinal plant in
East Asian countries and widely used for the treatment of
various kinds of cancer and other diseases [1]. 16-dehydro-
pregnenolone (16-DHP), a sterols compound isolated for
the first time from the active part of Solanum lyratum
Thunb., shows efficient anti-tumor activity on HeLa cell
line in our previous study [2].
16-DHP is an efficient inhibitor of 17a-hydroxylase arid
15a-reductase [3]. A patent declared that 16-DHP could
significantly decrease blood lipid in healthy volunteers or
patients with hyperlipidemia [4].
16-DHP has been developed as an oral hypolipidaemic
agent by Central Drug Research Institute (CDR!), Luc-
know. There were some limited data published on the phar-
macokinetics of 16-DHP in animals. Suryawanshi et al, [5]
reported the pharmacokinetics of 16-DHP and its metabo-
lites in rabbit plasma after oral administration. Singh et al,
[6] described an HPLC- UV method for the measurement
of 16-DHP in rat biological matrices after oral and intrave-
nous administration to rats. Intramuscular administration is
one of the common routes to administer sterols compounds,
which possess the similar structure to 16-DHP, to rats
parenterally. Compared with other routes of administra-
tion, a large enough amount of the drug can be readily
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deposited in muscle with little pain and local irritation. In
addition, possible degradation and metabolism could be
avoided by the intramuscular administration [7]. Thereby,
intramuscular administration could be a potential route of
dosing 16-DHP in clinical use. However, pharmacokinetic
information after intramuscular administration of 16-DHP
is not available up until now.
The purpose of this study was to investigate the pharma-
cokinetic profile of 16-DHP in rats after intramuscular
administration. The concentration of 16-DHP was deter-
mined by a desirable HPLC method with levonorgestrel as
the internal standard (IS). .
2 Materials and methods
2.1 Animal phannacokinetic study
Six male Sprague-Dawley rats (240 - 260 g) were purchased
from the Experimental Animal Center of Shenyang Phar-
o maceutical University (SCK-2oo7-004). They were housed
in a room with controlled temperature and humidity and
allowed to free access to food and water. They were fasted
overnight and allowed free access to water before drug
administration. They did not receive any drug treatment for
at least 30 days preceding the study. The protocol of the
animal study was in accordance with the Regulations of
Experimental Animal Administration issued by the State
Committee of Science and Technology of the People's
Republic of China .
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2.2 Experimental design
16-DHP, prepared at 20 mg/mL in propylene glycol-alco-
hol-normal saline (3: 4 : 3, v/v), was given via intramuscu-
lar injection as a bolus dose of 40 mg/kg. Blood samples
were collected from venous plexus of eye socket in heparin-
ized tubes before and 0.08,0.17,0.25,0.5,0.75,1,2,4,
6, 8 h after the dosing. Plasma sam'ples were obtained after
centrifugation at 3 000 rpm for 10 min and stored at - 20 ·c .
2.3 Sample preparation
To an aliquot of 200 flL plasma sample, 20 flL of acetoni-
trile and 20 flL of IS (300 ng/mL) were added, and the
mixture was extracted with 2 mL of n-hexane for 4 min.
After centrifugation (12 750 x g) for 10 min, the upper
organic layer was separated and transfered to another tube.
The extraction procedure was repeated and the combined
supernatant was evaporated to dryness at 40'C under a gen-
tle stream of nitrogen. The residue was reconstituted with
100 flL of mobile phase. A 20 flL aliquot of the resulting
solution was injected into the HPLC system f~r analysis.
2.4 Analytical method
16-DHP (purity, >99.0%, Figure 1A) was synthesized at
School of Pharmacy, Shenyang Pharmaceutical University.
Levonorgestrel (Is, Figure 1B) was purchased from Na-
tional Institute for the Control of Pharmaceutical and Bio-
logical Products (Beijing, China). Acetonitrile of HPLC
grade was obtained from Shandong Yuwang Chemical Fac-
tory (Shandong, China) . Purified water was purchased
from Hangzhou Wahaha Group Co., Ltd. (Hangzhou,
China). 16-DHP standard solutions and IS solution were
prepared in acetonitrile and stored at 4'C until used.
mined by analyzing spiked calibration samples at concentra-
tions of 20, 40, SO, 200, 400, 800 ng/mL (each concentra-
tion in duplicate) on three consecutive days. Samples were
quantified using the ratio of the peak area. Peak area ratios
of 16-DHP to that of IS were plotted against concentra-
tions, and standard curves were established using weighted
(1/x 2 ) least squares linear regression. The precision and
accuracy of the method were evaluated by determination of
QC samples at three concentration levels of 40, 200 and 640
ng/mL in six replicates on three validation days. The lower
limit of quantification (LLOQ) was defined as the lowest
concentration in the linear calibration curve. The extraction
recovery of 16-DHP was evaluated by comparing the mean
peak areas of the regular prepared QC samples (n = 6) at
40, 200 and 640 ng/mL with the mean peak areas of
spiked-after-extraction samples. The stabilities of 16-DHP
in rat plasma were evaluated by analyzing three replicates
of plasma samples at the concentrations of 40, 200 and 640
ng/mL. The spiked plasma samples were analyzed after
storage at 4 ·c for 24 h, at - 20'C for 45 days and after
three complete freeze/thaw cycles.
2.6 Phannacokinetic analysis
Pharmacokinetic parameters were calculated using non-
compartment model by Drug and Statistics (DAS, version
2.0). The values of maximum plasma concentration (CmaJl )
and time to reach CmaJl ( t maJl) were calculated from the
measured data. The area under the plasma concentration-
time curve from time zero to the time of the last measurable
concentration (AUC;O-l)) was calculated by the linear trape-
zoidal method. The terminal elimination rate constant (I<.)
was estimated by linear least squares regression of the ter-
minal portion of the plasma concentration-time curve. The
Figure 1 Structures of 16-DHP (A) and IS (levonorgestrel, B).
area under the plasma concentration- time curve from zero
to infinity (AUC;O-=)) was calculated using the trapezoidal
rule with extrapolation to infinity with Ke. The elimination
half-life (t 1/2) was calculated as 0.693/1<. .
OH
o
o
A
The HPLC system (Shimadzu, Japan)
consisted of a Shimadzu LC-6A pump, an
SPD-6A ultraviolet detector and a Shi-
madzu SCL-6B system controller. Data
were acquired and processed by Anastar
chromatography software (Tianjin Auto-
matic Science Instrument Co., Ltd.).
Separation was performed on a reversed-
HOphase Diamonsil CI8 column (250 mm x
4.6 mm, 5 flm, Dikma Technologies, Bei-
jing) at the temperature of 30 ·C. The iso-
cratic mobile phase consisted of acetoni-
trile-lO mM ammonium acetate (49 : 51, v/v) at a flow
rate of 1.0 mUmin. The detector was set at 238 nm, and
the injection volume was 20 flL.
2.5 Method validation
The specificity of the method was evaluated by analyzing
the blank plasma from six different sources of rats to test
interference at the retention times of the analyte and inter-
nal standard. The linearity of the assay method was deter-
3 Results and discussion
3.1 Otromatographic conditions
Wavelength of 238 nm which is the maximum absorption of
16-DHP was chosen for UV detection in this assay .
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Figure 2 Typical chromatograms of blank plasma (A), blank plasma
spiked with 16-DHP (1Loo, 20 ng/mL) and IS (8), and plasma
sample obtained from a rat after intramuscular administration of
16-0HP (C). 1, IS; 2, 16-DHP.
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Figure 2 shows the typical chromatograms of the blank
plasma sample, blank plasma sample spiked with 16-DHP
(LLOQ, 20 ng/mL) and IS, and a rat plasma sample
obtained after a single dose of 40 mg/kg. No interfering
endogenous substances were observed at the retention times
of 16-DHP and IS.
The method presented excellent linearity over the con-
centration range of 20 - 800 ng/mL with the correlation
coefficient of 0.9951. The typical equation of the calibra-
tion curve was y = 7. 700 X 10- 3 X + 1. 690 X 10- 1 (r =
0.9951), where y represents the ratio of 16-DHP peak area
to that of IS, and x represents the plasma concentration of
16-DHP. The LLOQ was 20 ng/mL with RSD values below
8.9%, and RE values were between -11.9% and 9.3%
(n = 6).
The precision and accuracy of the method were evaluated
with QC samples at concentrations of 40, 200, and 640 ng/
mL. The results are shown in Table 1. The intra- and inter-
day precisions of the QC samples were less than 3.7% and
14.5%, respectively. The accuracy was less than -8.1%.
In HPLC assay, internal standards are used for the accurate
quantification of concentrations. Levonorgestrel gave simi-
lar chromatographic profile and extraction recovery compa-
ring with that of 16-DHP, and was finally selected as the
internal standard.
3.3 Method validation
3.2 Internal standard
The response of 16-DHP was low and the chromato-
graphic peak shape is abnormal when using the mobile
phase consisting of acetonitrile and water. Formic acid,
phosphoric acid and ammonium acetate were attempted as
the modifier, and ammonium acetate was selected because
it could improve the response of the analyte and achieve
good peak shape. The mobile phase was finally optimized
as acetonitrile-l0 roM ammonium acetate buffer (49 : 51,
v/v) at a flow rate of 1.0 mUmin.
Thble 1 Precision (RSO) and accuracy (RE) of the HPLC method to
determine 16-0HP in rat plasma (n = 6)
The mean extractiQn recoveries of 16-DHP from plasma at .
three concentrations were (60.4 ± 3.4)%, (74.4 ± 1.4)% and
(67.5 ± 5.1)% (n = 6). The extraction recovery of the IS
was (72.1±2.3)%.
The RE values for all stability samples were within
± 10.5%'. It indicated that 16-DHP was stable in these
storage conditions.
Concentrations of RSO (%)
16-0HP(nglmL) Intra-day Inter-day
40 3.3 8.7
200 3.4 14.5
640 3.7 12.9
RE
(%)
5.9
1.6
-8.1
3.4 Phannacokinetic study
The validated analytical method was applied to the assay of
16-DHP in rat plasma after a single dosing by intramuscular
injection into male Sprague-Dawley rats with 40 mg/kg.
Mean plasma concentration-time profile after intramuscular
injection of 16-DHP is presented in Figure 3. The pharma-
cokinetic parameters of 16-DHP derived by non-compart-
mental analysis using DAS 2.1 program are summarized in
Table 2.
There were a few studies on pharmacokinetics of 16-
DHP. Singh et aI. [6] reported the pharmacokinetic prop-
erties of 16-DHP following a single intravenous dose (18
mg/kg) in rats. Suryawanshi et aI. [5] exhibited the phar-
macokinetic data of 16-DHP in rabbit after oral administra-
tion (40 mg/kg). After intramascular administration of 16-
DHP, the time to reach peak concentration [t ma.. (0.38 ±
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Pharrnacokinetic parameters Mean ± SD
Figure 3 Mean plasma concentration time profile in rats after intra-
muscular administration of 16-DHP.
ThbIe 2 Pharrnacokinetic parameters of 16-DHP in rat plasma after a
single dose of 40 mglkg of 16-DHP in six rats
The pharmacokinetics of 16-OHP in rats after intramuscular
administration was investigated using a specific and precise
HPLC method. According to the pharmacokinetic data ob-
tained, it is concluded that 16-0HP is absorbed quickly and
eliminated rapidly in rats after intramuscular injection.
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4 Conclusion
16-0HP exhibited potential anti-tumor actlVlty in our
previous study, and chronic toxicity studies demonstrated
that this drug is free from any untoward effects. and posses-
ses a suitable therapeutic window [5]. It would appear to
be a potential therapeutic tool for the treatment of certain
kinds of tumor in the future. Considering the structure of
16-0HP, intramuscular injection may be a probable admin-
istration route, although further studies are still needed.
876
289±25
O.38±O.14
2.5±1.1
544± 73
621 ± 116
2.2±O.4
3.4± 1.2
67± 13
229±69
4 5
Time (h)
32
c (JLglL)
t (h)
t1/2 (h)
AUC«().,) (ng' h/mL)
AU~().~) (ng' h/mL)
MRT«().,) (h)
MRT«().~)(h)
CLzlF(U(h'kg)]
VzlF(Ukg)
3 350
~300
c
';;'250
o
.~ 200
~ 150u
c8 100
os
~ 50
os
c:: 0 -t'--...,.--""T"'--r---,----.----,r--,....---r-
o
0.14)h] was shorter than that obtained after oral adminis-
tration in rabbit ( t max' O. 75 h) [6], suggesting that 16-0 HP
is absorbed more quickly after intramuscular injection in
rats. The clearance (CLzlF) of 16-OHP in rats [(67 ± 13)
U(h'kg)] was greater than that obtained in rabbit (4.91
Uh) [6]. and the value of elimination half-life[ t 112, (2.5
± 1. 1) h] of 16-0 HP was shorter than the corresponding
value reported in rabbit (t 1l2 , 6.0 h). These differences are
probably due to the differences in metabolism with routes
of administration of the drug. As total clearance is the gen-
uine kinetic parameter controlling drug exposure, this fact
also explains the low plasma levels detected, AVC (0-1) [(544
±73)ng'h/mL) and the short MRT(0-Id(2.2±0.4)h] in
plasma following intramuscular administration.
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